IP Library › Granted Patent US 9,439,997
Granted Patent B2
US 9,439,997 · App. 11/400,849 · Granted Sep 13, 2016

Reinforced absorbable multilayered hemostatis wound dressing

Inventors: Anne Jessica Gorman (Hightstown, NJ); Sanyog Manohar Pendharkar (Edison, NJ); Guanghui Zhang (Belle Mead, NJ); Liliana Bar (Rehovot, IL); Israel Nur (Moshav Timorim, IL); Roberto Meidler (Holon, IL)
Assignees: Ethicon, Inc.; Omrix Biopharmaceutical, Inc.
A61L15/26A61L15/28A61L15/32A61L15/44A61L15/64B32B5/022B32B5/024B32B5/026B32B5/26B32B23/02B32B23/10B32B27/36A61L2300/418A61L2300/608A61L2400/04B32B2250/20B32B2262/0276B32B2262/06B32B2262/062B32B2307/726B32B2556/00Y10T442/2525
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 9,439,997
App. No.
11/400,849
Filed
Apr 10, 2006
Granted
Sep 13, 2016
Kind
B2
Examiner
CAO, PING
Art Unit
1611
USPC
424/445
Abstract

The present invention is directed to a reinforced absorbable multilayered hemostatic wound dressing comprising a first absorbable nonwoven fabric, a second absorbable woven or knitted fabric, thrombin and/or fibrinogen.

Claims (9)

1. A hemostatic multilayered wound dressing comprising a first carrier layer with thrombin and fibrinogen, each is in the form as a dispersed powder, wherein the first carrier layer is an absorbable nonwoven fabric having a basis weight of about 0.01 to 0.2 g/in 2 that comprises glycolide/lactide copolymer and a staple fiber having a length from about 1.0 to 1.3 inches that is derived from fiber of about 1 to 4 denier per filament, and one or more second absorbable woven or knitted fabric having a basis weight of about 0.001 to 0.2 g/in 2 that comprises oxidized regenerated cellulose that reinforces the first carrier layer and is separate from the dispersed powders, wherein the multilayered dressing has a basis weight of about 0.1 to 1.0 g/in 2 , wherein the first absorbable nonwoven fabric comprises from about 70 to 95% by molar basis of polyglycolide and the remainder polylactide.

2. The multilayered dressing of claim 1 , where the staple fiber is crimped.

3. The multilayered dressing of claim 1 , wherein the thrombin activity on the multilayered dressing ranges from about 20 to 500 IU/cm 2 , and the fibrinogen amount on the multilayered dressing ranges from about 2 to 15 mg/cm 2 .

4. A hemostatic multilayered dressing comprising a first carrier layer with thrombin and fibrinogen, each is in the form as a dispersed powder, wherein the first carrier layer is an absorbable nonwoven fabric comprising glycolide/lactide copolymer and a staple fiber having a length from about 0.75 to 1.5 inch, a second absorbable woven or knitted fabric that is a reinforcing layer attached to the first carrier layer and is separate from the dispersed powders comprising oxidized regenerated cellulose, wherein the glycolide/lactide copolymer comprises from about 70 to 95% by molar basis of polyglycolide and the reminder polylactide, the thrombin activity on the multilayered dressing ranges from about 20 to 500 IU/cm 2 , the fibrinogen amount on the multilayered dressing ranges from about 2 to 15 mg/cm 2 .

5. The multilayered wound dressing according to claim 3 , wherein the dressing is sterilized.

6. The multilayered wound dressing according to claim 4 , wherein the dressing is sterilized.

7. A hemostatic multilayered wound dressing comprising a first absorbable nonwoven fabric and thrombin and fibrinogen as dispersed powders; one or more second absorbable woven or knitted fabric that comprises oxidized regenerated cellulose.

8. A hemostatic multilayered wound dressing as set forth in claim 1 or 4 wherein the fibrinogen amount is between 5-10 mg/cm 2 .

9. A hemostatic multilayered wound dressing as set forth in claim 1 or 4 wherein the weight ratio of the fibrinogen to the carrier and reinforcing layers is in the range of 0.26:1 to 0.52:1.

Assignments (2)
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Nov 9, 2016
From: ETHICON, INC.
To: OMRIX BIOPHARMACEUTICALS, INC.
Reel/Frame 040271/0764 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Jul 19, 2006
From: GORMAN, ANNE JESSICA; PENDHARKAR, SANYOG MANOHAR; ZHANG, GUANGHUI; BAR, LILIANA; NUR, ISRAEL; MEIDLER, ROBERTO
To: ETHICON, INC.; OMRIX BIOPHARMACEUTICAL, INC.
Reel/Frame 018111/0474 →
Continuity (4)
Continuation In Part 11252175 · Oct 17, 2005
Provisional Application 60696258 · Jul 1, 2005
Provisional Application 60620539 · Oct 20, 2014
Related Publication 20060257458A1 · Nov 16, 2006